Compare Davita Inc (DVA) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.09. The key difference: Davita Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| DVA | GPTY | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $235.71 | $50.52 |
52-Week Low | $103.87 | $34.73 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
GPTY trades at $43.50, down 2.2% today, with technical indicators showing mixed signals amid neutral overall momentum. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.30-$0.38. Support levels cluster around $43-44 while resistance sits at $45-46. Recent coverage highlights GPTY's focus on AI and tech exposure through option premium strategies, though some analysts question sustainability of current performance levels.
The outlook remains balanced with income generation from weekly dividends offset by technical weakness. Key risks include concentration in tech sector volatility and dependency on option strategy performance. Analyst sentiment appears divided between income-focused appeal and concerns about NAV erosion potential in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
